Results 31 to 40 of about 165,965 (304)

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis

British medical journal
Objective To evaluate the comparative efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults with type 2 diabetes.
H. Yao, A. Zhang, Delong Li, Yuqi Wu, Chong-Zhi Wang, Jin-Yi Wan, Chun-Su Yuan   +6 more
semanticscholar   +1 more source

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

Circulation, 2023
BACKGROUND: Sodium glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone all individually reduce cardiovascular, kidney, and ...
B. Neuen, H. Heerspink, P. Vart, B. Claggett, Robert A. Fletcher, Clare Arnott, J. de Oliveira Costa, M. Falster, Sallie-Anne Pearson, Kenneth W. Mahaffey, B. Neal, R. Agarwal, G. Bakris, V. Perkovic, S. Solomon, M. Vaduganathan   +15 more
semanticscholar   +1 more source

Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP‐1 Receptor Agonists

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi, Mohanad A. Alkuwaiti, Yazeed B. Alaql, Ahmed K. Alsaif, Ahmed A. Alessa, Meshari Ayed Alharbi, Mohammed Alfalah, Saud A. Alnaaim, Sajjad M. AlHaddad, Ahmed Y. Azzam   +9 more
wiley   +1 more source

A Scoping Review on Recent Advances in Antidiabetic Medications: From GLP-1 Receptor Agonists to Dual and Triple Agonists

Advances in Clinical Pharmacology and Therapeutics
The management of type 2 diabetes mellitus (T2DM) has evolved substantially with the development of incretin-based therapies targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide (GIP) receptor, and ...
Gulali Aktas
doaj   +1 more source

The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions

EClinicalMedicine
Summary Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed obesity management, offering substantial weight loss and metabolic benefits. This review examines their expanding role, evaluating efficacy compared to alternative treatments,
Areesha Moiz, K. Filion, Michael A Tsoukas, O. Yu, Tricia M. Peters, Mark J. Eisenberg   +5 more
semanticscholar   +1 more source

GLP-1 receptor agonists: an updated review of head-to-head clinical studies

Therapeutic Advances in Endocrinology and Metabolism, 2021
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while having a low risk of hypoglycemia. Some also have documented cardiovascular benefit.
Jennifer M. Trujillo, Wesley Nuffer, Brooke A. Smith   +2 more
semanticscholar   +1 more source

Safety and Efficacy of GLP‐1 Receptor Agonists in Adults With Epilepsy, Obesity, and Type 2 Diabetes

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Managing obesity in patients with epilepsy is complicated by the weight‐gaining properties of essential antiseizure medications (ASMs) such as valproate and pregabalin. We evaluated the safety and efficacy of initiating glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in this population.
Hyoshin Son, Inyoung Hwang, Sang Won Lee, Yun Kim   +3 more
wiley   +1 more source

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data

Diabetes, Metabolic Syndrome and Obesity, 2020
Richard A Chudleigh,1 Julia Platts,2 Stephen C Bain1,3 1Singleton Hospital, Swansea Bay University Health Board, Swansea, UK; 2Diabetes Centre, University Hospital Llandough, Cardiff and Vale University Health Board, Cardiff, UK; 3Diabetes Research Unit ...
Chudleigh RA, Platts J, Bain SC
doaj  

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia

Clinical Medicine Insights: Endocrinology and Diabetes, 2021
A relatively recent addition to the arsenal of antidiabetic drugs used for the treatment of type 2 diabetes mellitus (T2DM) has been the “incretin mimetics,” a group of drugs that work on the glucagon-like peptide-1 (GLP-1) receptor and enhance insulin ...
Daria Ja’arah, Mazhar Salim Al Zoubi, Gamal Abdelhady, Firas Rabi, Murtaza M Tambuwala   +4 more
doaj   +1 more source

Canagliflozin Alleviates Diabetic Glomerular Endothelial Injury via Melibiose in a Microbiota‐Dependent Manner

Advanced Science, EarlyView.
Canagliflozin treatment reshapes the gut microbiota in DKD and elevates levels of melibiose, a metabolite derived from Roseburia intestinalis. Melibiose directly binds to and enhances the enzymatic activity of glyoxalase 1, leading to decreased methylglyoxal accumulation.
Wei Zhang, Yi Song, Changkun Li, Yuanyuan Luo, Mingwei Shao, Feng Guo, Fangyi Wei, Xunjie Fan, Wenwen Guo, Fengmei Xu, Yanhong Sang, Dongming Zhang, Yanhong Zhou, Lianwei Wang, Zhiqiang Kang, Yingjun Yang, Chunhua Song, Yanxia Liu, Xiaojun Ma, Jiao Wang, Chong Li, Shengnan Ma, Lin Zhao, Zhi Qin, Guolan Xing, Qiubo Zhao, Jun Li, Shumin Song, Dan Zhao, Ting Huang, Qingzhu Wang, Yanyan Zhao, Guijun Qin   +32 more
wiley   +1 more source